argenx SE/$ARGX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Ticker

$ARGX
Sector
Health
Primary listing
NASDAQ

Employees

1,599
Headquarters
Amsterdam, Netherlands
Website
argenx.com

argenx SE Metrics

BasicAdvanced
$51B
45.00
$18.75
-
-

Bulls say / Bears say

argenx delivered $949 million in global product net sales for Q2 2025—up 97% year-over-year and 19% sequentially—demonstrating robust commercial execution and accelerating demand for Vyvgart across all approved indications (Investing.com)
The FDA’s April 2025 approval of the Vyvgart Hytrulo prefilled syringe enables at-home self-administration for generalized myasthenia gravis and CIDP patients, poised to expand patient access, compete with oral therapies and drive earlier line use (Reuters)
Through its Immunology Innovation Program, argenx has nominated four new pipeline candidates (ARGX-213, ARGX-121, ARGX-109 and a first-in-class sweeping antibody), with Phase 1 readouts expected in H2 2025 and H1 2026, underscoring a sustainable runway for future growth (argenx)
Argenx shares fell more than 8% in premarket trading after reporting Q1 2025 earnings of $2.58 per share on $790 million in sales—despite beating expectations, the market reacted negatively to execution not exceeding lofty forecasts, highlighting sensitivity to delivery risk (Investors.com)
Competition in the FcRn antagonist space is intensifying, with UCB’s Rystiggo, Immunovant’s IMVT programs and Viridian Therapeutics’ VRDN candidates nearing late-stage trials, posing a risk of share erosion for Vyvgart if rival therapies gain traction (TipRanks)
argenx recorded total operating expenses of $668 million in Q1 2025, driven by $309 million in R&D and $276 million in SG&A, which may continue to pressure near-term profitability until economies of scale are achieved (argenx)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

argenx SE News

AllArticlesVideos
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

CNBC Television2 months ago
3 Healthcare Pathbreakers With Long-Term Tailwinds

3 Healthcare Pathbreakers With Long-Term Tailwinds

MarketBeat2 months ago
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARGX

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs